Skip to Main Content

Author Details

Joseph B Bolen
University of California San Francisco
1977
183
78
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
34546978Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer.JCI Insight2021
32258034Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies.Front Cell Dev Biol2020
33590360Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence.J Mammary Gland Biol Neoplasia2020
26101564MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors.ACS Med Chem Lett2015
24335104Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.Blood2014
23493743Takeda's Oncology Discovery Strategy.Jpn J Clin Oncol2013
22439935Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.Cancer Cell2012
21400028Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.Cancer Chemother Pharmacol2011
22016509Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.Clin Cancer Res2011
21903769Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.Clin Cancer Res2011
20129059Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.Mol Cell2010
20724731Pillars article: the CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. 1994.J Immunol2010
20525923MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.Blood2010
20160034Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.Cancer Res2010
19360080An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.Nature2009
17360485Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.Proc Natl Acad Sci U S A2007
16897318Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model.Mol Imaging Biol2006
11410123A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells.BMC Immunol2001
18432706Assessment of the effects of tyrosine protein kinase inhibitors.Curr Protoc Immunol2001
18432705Immune-complex assays for tyrosine protein kinases.Curr Protoc Immunol2001
10644997The MMAC1 tumor suppressor phosphatase inhibits phospholipase C and integrin-linked kinase activity.Oncogene2000
10903730B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase.J Immunol2000
10208437Transcriptional analysis of the PTEN/MMAC1 pseudogene, psiPTEN.Oncogene1999
10364453Identification and characterization of a myristylated and palmitylated serine/threonine protein kinase.Biochem Biophys Res Commun1999
10224128Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk.J Biol Chem1999
10327049Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1.Oncogene1999
10022807Phenotypic analysis of human glioma cells expressing the MMAC1 tumor suppressor phosphatase.Oncogene1999
9778529A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.Curr Biol1998
9622068Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer.Cancer Res1998
9009164Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines.Int J Cancer1997
9177269Palmitylation of Src family tyrosine kinases regulates functional interaction with a B cell substrate.Biochem Biophys Res Commun1997
9120258Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex.J Immunol1997
9143693Leukocyte protein tyrosine kinases: potential targets for drug discovery.Annu Rev Immunol1997
9275205The Syk and ZAP-70 SH2-containing tyrosine kinases are implicated in pre-T cell receptor signaling.Proc Natl Acad Sci U S A1997
9408234Signaling pathways controlling trophoblast cell differentiation: Src family protein tyrosine kinases in the rat.Biol Reprod1997
8576138Endogenous reactive oxygen intermediates activate tyrosine kinases in human neutrophils.J Biol Chem1996
9064347RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells.J Exp Med1996
8900205Specific association of tyrosine-phosphorylated c-Cbl with Fyn tyrosine kinase in T cells.J Biol Chem1996
8947048The Syk protein tyrosine kinase can function independently of CD45 or Lck in T cell antigen receptor signaling.EMBO J1996
8823293HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression.J Clin Invest1996
8688094BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells.Science1996
8790395Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase.Proc Natl Acad Sci U S A1996
8833397Role of tyrosine phosphorylation in radiation-induced cell cycle-arrest of leukemic B-cell precursors at the G2-M transition checkpoint.Leuk Lymphoma1996
8832289Expression of exogenous p59fyn modulates signaling in an immature B cell line, WEHI-231.Immunol Lett1996
8882955Role of hydroxyl radicals in radiation-induced activation of lyn tyrosine kinase in human B-cell precursors.Leuk Lymphoma1996
8557695Selective activation of T cell kinase p56lck by Herpesvirus saimiri protein tip.J Biol Chem1996
8551220The SH3 domain of p56lck binds to proline-rich sequences in the cytoplasmic domain of CD2.J Exp Med1996
8631803Signal transduction through the beta1 integrin family surface adhesion molecules VLA-4 and VLA-5 of human B-cell precursors activates CD19 receptor-associated protein-tyrosine kinases.J Biol Chem1996
8630734TCR activation of ZAP70 is impaired in CD4+CD8+ thymocytes as a consequence of intrathymic interactions that diminish available p56lck.Immunity1996
8626437Physical and functional interactions between Lyn and p34cdc2 kinases in irradiated human B-cell precursors.J Biol Chem1996
  • 1 - 50 of 183

Recommended Authors

Yael Babichev
2Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital.
Career Start Year 2001
Number of shared co-authors 0
Karen H Martin
West Virginia University Cancer Institute, West Virginia University
Career Start Year 1993
Number of shared co-authors 0
J Paul Secrist
Oncology R&D
Career Start Year 1990
Number of shared co-authors 1
Johanna Ten Hoeve
California Nanosystems Institute, University of California los angeles
Career Start Year 1990
Number of shared co-authors 2
Jami Willette-Brown
Center for Cancer Research, National Cancer Institute
Career Start Year 1989
Number of shared co-authors 0
Stephan M Feller
Institute of Molecular Medicine, Martin-Luther-University of Halle-Wittenberg
Career Start Year 1989
Number of shared co-authors 0
Kaoru Saijo
Helen Wills Neuroscience Institute, University of California berkeley
Career Start Year 1988
Number of shared co-authors 0
Hamid Band
University of Nebraska Medical Center
Career Start Year 1985
Number of shared co-authors 2
Michael F Moran
Hospital for Sick Children, University of Toronto
Career Start Year 1985
Number of shared co-authors 0
Toshio Kitamura
The University of Tokyo.
Career Start Year 1984
Number of shared co-authors 2
Jill Meisenhelder
Salk Institute
Career Start Year 1984
Number of shared co-authors 1
Nicholas K Tonks
University of Washington
Career Start Year 1982
Number of shared co-authors 1
Patrick Auberger
Universite Cote d'Azur, INSERM U5
Career Start Year 1982
Number of shared co-authors 3
Sylvain Meloche
Institute for Research in Immunology and Cancer
Career Start Year 1982
Number of shared co-authors 0
Siu-Pok Yee
University of Connecticut Health Center
Career Start Year 1981
Number of shared co-authors 0
Robert E Lewis
University of Nebraska Medical Center
Career Start Year 1980
Number of shared co-authors 0
Brian Seed
Center for Computational and Integrative Biology, Massachusetts General Hospital
Career Start Year 1980
Number of shared co-authors 0
Donald L Durden
Atrium Health-Levine Cancer Institute
Career Start Year 1979
Number of shared co-authors 3
Peter S Linsley
8Benaroya Research Institute
Career Start Year 1978
Number of shared co-authors 2
Sara A Courtneidge
Oregon Health & Science University
Career Start Year 1977
Number of shared co-authors 0
Daniel W McVicar
National Cancer Institute
Career Start Year 1976
Number of shared co-authors 0
Karin D Rodland
Oregon Health and Science University
Career Start Year 1973
Number of shared co-authors 2
Jack E Dixon
University of California
Career Start Year 1972
Number of shared co-authors 2
Tak W Mak
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1970
Number of shared co-authors 2
Jonathan M Backer
Albert Einstein College of Medicine
Career Start Year 1970
Number of shared co-authors 2
Charles J Sherr
St. Jude Children's Research Hospital
Career Start Year 1968
Number of shared co-authors 2
Tony Hunter
Salk Institute for Biological Studies
Career Start Year 1968
Number of shared co-authors 3
Shigeo Koyasu
RIKEN Center for Integrative Medical Sciences (IMS)
Career Start Year 1966
Number of shared co-authors 1
John T Parsons
The School of Medicine, University of Virginia
Career Start Year 1966
Number of shared co-authors 1
Lloyd J Old
Ludwig Institute for Cancer Research
Career Start Year 1959
Number of shared co-authors 1

Collaborators

Joan S Brugge
Co-authored papers 5
Shohreh Amini
Co-authored papers 5
Tony Pawson
Co-authored papers 3
Arthur Weiss
University of California san francisco
Co-authored papers 3
Scott R VandenBerg
University of California san francisco
Co-authored papers 2
Peter A Kiener
BioKien LLC
Co-authored papers 2
Ronald E Gress
National Cancer Institute, National Institutes of Health
Co-authored papers 2
Owen N Witte
University of California los angeles
Co-authored papers 2
Neil E Bhola
Zai Lab (US) LLC
Co-authored papers 1
Maryalice Stetler-Stevenson
National Cancer Institute, National Institutes of Health
Co-authored papers 1
Kelechi Nwachuku
Co-authored papers 1
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 1
Mark H Ginsberg
University of California
Co-authored papers 1
George Mulligan
Co-authored papers 1
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 1
Lewis C Cantley
Co-authored papers 1
Carl H June
University of Pennsylvania Department of Pathology & Laboratory Medicine
Co-authored papers 1
Rex H Lee
Co-authored papers 1
David L Wiest
Fox Chase Cancer Center
Co-authored papers 1
Jorge Silvio Gutkind
Moores Cancer Center, University of California San Diego
Co-authored papers 1
Jennifer R Grandis
University of California san francisco
Co-authored papers 1
Daniel E Johnson
University of California San Francisco
Co-authored papers 1
Pierre P Massion
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Co-authored papers 1
Aaron Hechmer
University of California san francisco
Co-authored papers 1
Meenhard Herlyn
Ellen and Ronald Caplan Cancer Center, The Wistar Institute
Co-authored papers 1
William E Evans
Departments of Oncology. St. Jude Children's Research Hospital
Co-authored papers 1
Stephen B Keysar
University of Colorado Denver
Co-authored papers 1
Ritu Roy
University of California San Francisco.
Co-authored papers 1
Alexander D Borowsky
University of California Davis Health
Co-authored papers 1
Brian Van Ness
University of Minnesota
Co-authored papers 1
Release 1.2